HALIFAX, March 12, 2018 /CNW/ - kneat.com, inc. (TSXV: KSI) ("Kneat" or the "Company") is pleased to announce that it intends to complete a brokered private placement for aggregate gross proceeds of up to $5.0 million (the "Offering"). The Company intends to issue 5,555,556 common shares at an issue price of $0.90 per common share. The Offering will be completed through a syndicate of agents to be led by Echelon Wealth Partners Inc. (the "Agents") in which the Agents will raise up to approximately $5.0 million on a commercially reasonable best efforts basis at a price of $0.90 per common share. The Company has agreed to pay the Agents a cash commission equal to six percent (6%) of the gross proceeds raised as part of the Offering plus warrants entitling the Agents to purchase the number of common shares of the Company that is equal to six percent (6%) of the common shares sold as part of the Offering. The cash and warrant commissions will exclude up to $1.0 million of president's list orders. The warrants will have an exercise price of $0.90 per common share for a period of 18 months.  

The gross proceeds of the Offering will be used to expand the Company's sales and marketing function to service its new customers and to further expand the customer pipeline, accelerate the development of the Kneat Gx platform to increase functionality and to fund ongoing operating costs and working capital requirements.

The Offering is scheduled to close on or about April 15, 2018 and is subject to certain conditions including, but not limited to, completion of satisfactory due diligence investigations and receipt of all necessary regulatory approvals, including the approval of the TSX Venture Exchange. All securities issued pursuant to the Offering will be subject to a statutory four-month hold period in accordance with Canadian securities legislation.

About Kneat

Kneat develops and markets the next generation Kneat Gx software platform.  Multiple business processes can be configured on the platform from equipment to computer system validation, through to production record execution and quality document management.  Kneat Gx allows users to author, review, approve, execute testing online, manage any exceptions and post approve final deliverables in a controlled FDA 21 CFR Part 11/ Eudralex Annex 11 compliant platform.  Macro and micro report dashboards enable powerful oversight into all systems, projects and processes world wide.  Customer case studies are reporting productivity improvements in excess of 100% and a higher compliance standard.  For more information visit www.kneat.com.

Cautionary and Forward-Looking Statements

Except for the statements of historical fact contained herein, certain information presented constitutes "forward-looking information" within the meaning of applicable Canadian securities laws.  Such forward-looking information, includes, but is not limited to, the ability of the Company to complete the private placement, the use of the proceeds from the private placement, the Company's business development activities, the ability to increase functionality of the Kneat Gx platform, the ability to scale the use of Kneat within the customer and the compliance of the Kneat Gx platform under regulatory audit and inspection.  While such forward-looking statements are expressed by the Company, as stated in this release, in good faith and believed by the Company to have a reasonable basis, they are subject to important risks and uncertainties.  As a result of these risks and uncertainties, the events predicted in these forward-looking statements may differ materially from actual results or events.  These forward-looking statements are not guarantees of future performance, given that they involve risks and uncertainties.  The Company does not undertake any obligation to release publicly revisions to any forward-looking statement, except as may be required under applicable securities laws.  Investors should not assume that any lack of update to a previously issued forward-looking statement constitutes a reaffirmation of that statement.  Continued reliance on forward-looking statements is at an investors' own risk.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Kneat.com

View original content: http://www.newswire.ca/en/releases/archive/March2018/12/c3694.html